PDF电子书：分子疗法（2011）

tianzhang

! u3 I9 j' g, P8 p% n+ W1 O# W  o9 r. k
Molecular therapies3 H; F8 p! k  z. z
Dr. Zoltán Balajthy, Dr. János Aradi, Dr. Zoltán Balajthy, Dr. Éva Csősz, Dr. Beáta Scholtz, Dr. István Szatmári, Dr. József Tőzsér, Dr. Tamás Varga (2011)+ E) }4 o; a* Z% V8 T

$ J9 m8 u4 f- _University of Debrecen
! {: B- F" L- r& j% K. A2 ?Copyright © 2011 The project is funded by the European Union and co-financed by the European Social Fund., Manuscript completed: 17 November 2011
. z. s' f1 x* Z
! q: g) G/ j4 P0 j
0 f/ k1 l  p- ~: W) R+ [  ~6 X0 s( M/ X, }( M6 v8 F3 P2 C7 {
Index7 @1 s% c. y# n0 \( L* a9 l
1. 1. Functional Genomics
$ c9 b/ |" {- M8 A, ?/ c1 v1.1 Definitions
# |% Q4 W* C+ i- \9 m1.2 About diseases0 R  f# p/ @. e8 ~
1.3 Approaches to understanding disease mechanisms
+ g: F3 J$ z, g0 E/ _) I; m6 Z# Y1.3.1 Gene expression is regulated in several basic ways
9 R- I' j+ k& `& l2 t1.3.2 Microarrays: functional genomics in cancer research
% B* T  n$ L0 x$ V* e9 R1.3.3 A Variety of Genetic Alterations Underlie Developmental Abnormalities and Disease  n. q: F: x: n& f0 r: K
1.3.4 Genomic microarrays. A3 z$ Z8 F& d6 q4 |
2. 2. Recombinant proteins
5 }+ m' o* ~' ]0 w6 F7 X' p2.1 Overview: Protein pharmaceuticals
, h" u) d  t% Q2.2 Cell-free systems: In vitro transcription and translation
" z- s' L: N' g. t2.3 Recombinant protein expression in isolated cells (cell culture), B0 V9 _3 J. t+ L0 |9 W0 ~( @
2.4 Non-prokaryotic expression systems
1 E# w! T9 d4 g  ^& ~2.4.1 Cloning in Pichia pastoris
9 p' y3 D  e. I1 S0 R' p- ]2.4.2 Baculovirus mediated protein expression in insect cells
( J: a3 `. ]5 b& @# h2.4.3 Mammalian expression systems# s/ e+ e4 i7 ?% j
2.5 Purification of recombinant proteins2 B* `9 r2 I& Z( w' i/ _
3. 3. Gene Therapy: Vectors and Strategies.( W$ |/ E1 C6 l0 r$ t
3.1 Vectors for Gene Therapy; ]/ g) J, f: G! D4 e2 k) m
3.2. Types of gene transfer, vectors for gene therapy
& D; Z; p" [& t( d3.3. General gene therapy strategies
$ K  A# ?: V5 G3.4. Human gene therapy8 l9 n: \/ q! ?/ Z. |% m% J2 D: b
4. 4. Protein replacement therapies.  n! G- a& {, X% f& A3 j
5. 5. Recombinant antibodies and the phage display technology8 Y% W; M: k& R( Y7 \
5.1. Introduction
* \* m3 z3 ~/ U4 o6 A5 |. }7 I. q3 H8 a5.1.1. The structure of antibodies and their production in the body4 h5 x/ c! r. i' Z; @/ S+ t
5.1.2. Antigen-antibody binding
2 q0 i( F" P% m. |5.2. The production of therapeutic antibodies- D/ C- l% p, x. w
5.2.1. The production of antibodies in hybridoma cells.8 h" o4 j5 v3 f4 \2 m6 Q
5.2.2. Humanized antibodies
4 h( B/ d' x$ E, j6 u" B5.2.3. Production of human antibodies/ j/ [& U" a  d4 z
5.3. Generation of antibodies by phage display
  S4 Q/ [/ l* d+ I' \5.3.1. The phage display technology, a  D* M. Q- W; y  m. A
5.3.2. Generation of phage libraries
. [! A( M# _, P) l( Z' b5.4. Administration of therapeutic antibodies  K5 w1 q7 g) @% ]) P$ p4 Q
6. 6. Anti-cytokine Therapy (sepsis).3 v! h. Q; p' l* J( |/ o
6.1. The consequences of developing inflammation& }4 H: I- [( O
6.2. Development of Inflammatory Response: Synthesis of Lipid Mediators
: a. U& @! m1 W$ T  P0 e, ]6.3. Role of the Liver in Maintenance of Homeostasis: Acute Phase Response
! Q. x( S$ G  E, f6 E) \6.4. Time-Course of the Inflammatory Response During Sepsis
6 J8 W0 d1 w1 c( f7. 7. Animal models and transgenesis in biotechnology; K8 A/ H5 I) v6 s
8. 8. Embryonic and adult stem cells in regenerative medicine I., h9 Q& k3 I$ M  m( a2 w
8.1 Embryonic stem cells( l5 F$ D8 d1 i. o% \" b
8.2 Somatic cell reprogramming into pluripotent stem cells! g/ v5 ~3 T# w" q  I! H
8.3 Adult stem cells
: ~  o4 ?. @7 ^0 X8 O- e% _9. 9. Embryonic and adult stem cells in regenerative medicine II.$ l% x2 F4 F4 h  B9 q# I7 N
9.1 Pluripotent stem cells for regenerative medicine
' u" I7 I1 a, e% B4 _3 R* h) w9.2 Clinical application of stem cells
3 n' X. t4 `# y+ d9.3 Stem cell therapy to cure various diseases$ e3 M9 o7 }' v& Q0 I
10. 10.        Cell Cycle and Cancer Therapy, p53 I.
2 e$ I2 e; k4 v4 P8 l  _10.1 Cell Cycle
3 j6 h9 o! X5 u" `( l* X- ?10.2. Mitogenic Signaling in Eukaryotic Cell Controls the Rate of Cell Division3 _$ f' R$ K# p6 Z
10.3. Biochemical Events of Cell-cycle – in M Phase9 D% a( a5 r& L" c& _8 M
10.4. Protooncogenes
% Q& B4 n& ^' G10.5. ErbB/HER Receptors; T: K/ f9 e9 _  E+ S
10.6. Therapeutic targets
/ T! r5 Y. b2 d3 w11. 11. Cell Cycle and Cancer Therapy, p53 II.7 l5 ?, L2 ?+ h
11.1. Tumor Suppressor Genes and p53
! X  i$ M/ X, E11.2. Biochemical Pathways of Apoptosis and its Therapeutic Utilization
4 n3 ?4 u& V5 S0 [$ F! E12. 12. Gene Silencing Technologies.% H! a: H( u$ a
12.1 Introduction$ {; l, b4 a  w" q/ h
12.2 Action of antisense oligonucleotides& w% @. Y' n9 `
12.3 Chemical modifications of gene silencing oligonucleotides; general considerations
- C( q8 [  V2 ?4 E12.4 Inhibition of transcription by triple helix forming oligonucleotides
; s  N8 i/ O: P. Y. ^1 u) \5 G12.5 Gene silencing by ribozymes8 H5 q( O- J4 C% C/ }
12.6 Gene silencing with short RNA fragments
1 K: g1 w" h" [- U- j  P$ M4 `12.7 Important final note% o  B  L" ^( V  E

% A3 k. f1 L% h2 q  a# g( h) V* U4 T[hide][/hide]

mzaq2006

看看

mzaq2006

无法下载啊，扣了24个包包都不行

mzaq2006

是32个包包啊

goblinwang

学习学习

goblinwang

呵呵，我可以下载，估计，你不是使用网页自带的下载吧，记得以前论坛提起，尽量不用迅雷等下载软件，你在试试吧

xylan327

谢谢分享

xuguofeng

肌源性干细胞

石头111

干细胞研究重在基础

MIYAGI

嘿嘿......哈哈......呵呵.....哟~呼